Plenary Session – Global Development in Biotechnology Date: 24 July (Wednesday) 9:00 – 12:05 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
Senior Vice President Clinical Development, (JAPAC)
Oncology & Hematology Business Unit
Dr. David Fuller holds dual qualifications in Medicine and Pharmacy and serves as Senior Vice President, Clinical Development for Syneos Health’s Oncology Business Unit based in Sydney Australia. Dr. Fuller is an Industry veteran having over 30 years international experience developing and commercializing new products, as well as establishing and nurturing businesses in complex international environments. His R&D experience encompasses pre-clinical, clinical development and medical and regulatory affairs, with a therapeutic specialization in oncology clinical trials across multiple therapeutic agents and combinations. Dr. Fuller has successfully led five product approvals (US/EU) and has multiple FDA and EMEA interactions for major market both orphan and products. Prior to joining Syneos Health in 2010, Dr. Fuller worked for companies including Genzyme, Arana Therapeutics, Orphan Medical, Roche and Pfizer. Session Speech Title & Synopsis: Oncology Treatments - Creating Decision Driven Insights
Medical decision making in oncology is a critical activity yet highly complex. A broad range of parameters must be considered in a timely manner including disease stage, diagnostic test results, (increasingly complex) treatment options, side effects, patient and family preferences and values – plus what is possible within the framework and available resources of the healthcare environment. Importantly many treatment choices are affected by limited scientific evidence, availability of therapies or patient-specific factors.
This talk will review the rapidly changing oncology environment and review new tools, techniques and approaches to improve decision making in our increasingly complex oncology environment.